BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: SGLT-2 inhibitor
Date Journal Article title
2020 Korean Circ J Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease.
2020 Mar Diabetes Res Clin Pract Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
2020 Mar Cell Metab Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β.
2020 Korean Circ J Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model.
2020 Case Rep Endocrinol Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature.
2020 Feb J Atheroscler Thromb The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.
2020 Diabetes Metab Syndr Obes The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers.
2020 Mar Hosp Pract (1995) Link between body weight changes and metabolic parameters in drugs naïve jects with type 2 diabetes treated with canagliflozin monotherapy.
2020 Indian J Clin Biochem Empagliflozin Attenuates Renal and Urinary Markers of Tubular Epithelial Cell Injury in Streptozotocin-induced Diabetic Rats.
2020 Feb Cardiovasc Diabetol Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
2020 Feb Fundam Clin Pharmacol Empagliflozin attenuates transient cerebral ischemiareperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway.
2020 Clin Ther GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice.
2020 Jan Nephrol Dial Transplant Renal physiology of glucose handling and therapeutic implications.
2019 ESC Heart Fail Highlights in heart failure.
2020 Mar Biochem Biophys Res Commun The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
2020 Jan Clin Exp Pharmacol Physiol Sodium-glucose co-transporters and diabetic nephropathy: Is there a link with toll-like receptors?
2020 Jan Endocr Res Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
2019 F1000Res Recent advances in the treatment of chronic heart failure.
2020 Jan Int J Mol Sci No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
2019 J Prim Care Community Health Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus.
2019 Dec Cardiol Rev Cardiovascular Outcomes with the Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials.
2020 Diabetes Ther Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
2019 Nov Cureus Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis.
2020 Neurohospitalist Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and "Sweet Pee Encephalopathy" in Perioperative Hospital Management.
2020 Apr J Clin Endocrinol Metab Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
2019 Diabetes Metab Syndr Obes Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin.
2020 Eur J Heart Fail European Society of CardiologyHeart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
2019 Dec J Formos Med Assoc An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium-glucose cotransporter-2 inhibitors: A case report.
2020 Anaesthesist [Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication].
2019 Medicine (Baltimore) Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
2019 Nov Sci Rep Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
2019 Physiol Rep SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
2019 Nov BMJ Open Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
2019 Nov Cardiovasc Diabetol Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat dietstreptozotocin-induced diabetic rats.
2019 J Manag Care Spec Pharm Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
2019 Eur J Prev Cardiol Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
2019 BMJ Open Diabetes Res Care Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
2019 Front Endocrinol (Lausanne) Ketosis-Prone Type 2 Diabetes: A Case Series.
2020 ESC Heart Fail Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
2020 Diabetes Obes Metab The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
2019 Transplant Proc Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases.
2019 MMW Fortschr Med [SGLT-2-Inhibitors and kidney function].
2019 Endokrynol Pol Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor.
2020 J Med Econ Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
2019 J Assoc Physicians India Efficacy and Safety of Canagliflozin in Patients with Type II Diabetes Mellitus Inadequately Controlled on Triple Drug Therapy.
2019 Aug Cureus Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report.
2019 Diabetes Res Clin Pract The right place for Sulphonylureas today.
2019 Heart Fail Clin Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting.
2020 Can J Diabetes Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors.
2019 Expert Opin Pharmacother The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study.
2019 Adv Ther Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
2019 Am J Ther Acute Renal Failure With Cocaine and SGLT-2 Inhibitor.
2019 Diabetes Obes Metab Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
2019 PLoS One National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015.
2020 Diabetes Obes Metab Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.
2019 Jul Ann Intern Med Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
2019 Medicine (Baltimore) Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
2019 J Family Med Prim Care Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure.
2019 Kidney Int SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.
2019 Arterioscler Thromb Vasc ... SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice.
2019 Diabetes Ther Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?
2019 Case Rep Endocrinol A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes.
2019 Front Endocrinol (Lausanne) Clinical Use of DPP-4 Inhibitors.
2019 Kyobu Geka [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
2019 Diabetes Obes Metab Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
2019 Jun World J Diabetes Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications.
2019 Ann Pharmacother The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
2020 Jan Intern Med Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?
2019 Diabetes Obes Metab Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
2019 Iran J Basic Med Sci Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis.
2019 Expert Opin Drug Saf An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
2019 Diabetes Obes Metab Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
2018 Jun Rev Cardiovasc Med Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
2018 Jun Rev Cardiovasc Med Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
2019 Diabetes Obes Metab Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.